Comparison of voxel S-value methods for personalized voxel-based dosimetry of 177Lu-DOTATATE

11 January 2022


Keon Min Kim, Min Sun Lee, Min Seok Suh, Haniff Shazwan Muhd Safwan Selvam, Teik Hin Tan, Gi Jeong Cheon, Keon Wook Kang, Jae Sung Lee

VIEW RESEARCH HERE
COPY CITATION
Copied!

Abstract

Purpose

Voxel-based dosimetry is potentially accurate than organ-based dosimetry because it considers the anatomical variations in each individual and the heterogeneous radioactivity distribution in each organ. Here, voxel-based dosimetry for 177Lu-DOTATATE therapy was performed using single and multiple voxel S-value (VSV) methods and compared with Monte Carlo simulations. To verify these methods, we adopted sequential 177Lu-DOTATATE single-photon emission computed tomography and X-ray computed tomography (SPECT/CT) dataset acquired from Sunway Medical Centre using the major vendor's SPECT/CT scanner (Siemens Symbia Intevo).

Methods

The administered activity of 177Lu-DOTATATE was 7.99 ± 0.36 GBq. SPECT/CT images were acquired 0.5, 4, 24, and 48 h after injection in Sunway Medical Centre. For the multiple VSV method, VSV kernels of 177Lu in media with various densities were generated by Geant4 Application for Emission Tomography (GATE) simulation first. The second step involved the convolution of the time-integrated activity map with each kernel to produce medium-specific dose maps. Third, each medium-specific dose map was masked using binary medium masks, which were generated from CT-based density maps. Finally, all masked dose maps were summed to generate the final dose map. VSV methods with four different VSV sets (1, 4, 10, and 20 VSVs) were compared. Voxel-wise density correction for the single VSV method was also performed. The absorbed doses in the kidneys, bone marrow, and tumors were analyzed, and the relative errors between the VSV and Monte Carlo simulation approaches were estimated. Organ-based dosimetry using Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA/EXM) was also compared.

Results

The accuracy of the multiple VSV approach increased with the number of dose kernels. The average dose estimation errors of a single VSV with density correction and 20 VSVs were less than 6% in most cases, although organ-based dosimetry using OLINDA/EXM yielded an error of up to 123%. The advantages of the single VSV method with density correction and the 20 VSVs over organ-based dosimetry were most evident in bone marrow and bone-metastatic tumors with heterogeneous medium properties.

Conclusion

The single VSV method with density correction and multiple VSV method with 20 dose kernels enabled fast and accurate radiation dose estimation. Accordingly, voxel-based dosimetry methods can be useful for managing administration activity and for investigating tumor dose responses to further increase the therapeutic efficacy of 177Lu-DOTATATE.

Reference

  1. Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008). Treatment with the radiolabeled somatostatin analog [$^{177}$Lu-DOTA$^0$,Tyr$^3$]octreotate: Toxicity, efficacy, and survival. Journal of Clinical Oncology, 26(13), 2124–2130. https://doi.org/10.1200/JCO.2007.15.2553
  2. Hosono, M., Ikebuchi, H., Nakamura, Y., Nakamura, N., Yamada, T., Yanagida, S., Kitaoka, A., Kojima, K., Sugano, H., Kinuya, S., Inoue, T., & Hatazawa, J. (2018). Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.). Annals of Nuclear Medicine, 32(3), 217–235. https://doi.org/10.1007/s12149-018-1230-7
  3. Graves, S. A., Flynn, R. T., & Hyer, D. E. (2019). Dose point kernels for 2,174 radionuclides. Medical Physics, 46(11), 5284–5293. https://doi.org/10.1002/mp.13789
  4. Bolch, W. E., Bouchet, L. G., Robertson, JS., Wessels, B. W., Bednarz, G., Brill, A. B., Howell, R. W., Meredith, R. F., Sgouros, G., Thomas, S. R., Fisher, D. R., Hamm, M. T., & Poston, J. W., Sr. (1999). MIRD pamphlet No. 17: The dosimetry of nonuniform activity distributions—Radionuclide S values at the voxel level. Journal of Nuclear Medicine, 40(1), 11S–36S.
  5. Dieudonné, A., Hobbs, R. F., Lebtahi R., Boucek, J. A., r, Fernández, M., Sgouros, G., & Franken, P. R. (2013). Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: Comparison between dose kernel convolution and direct Monte Carlo methods. Journal of Nuclear Medicine, 54(2), 236–243. https://doi.org/10.2967/jnumed.112.105825
  6. Brosch-Lenz, J., Uribe, C., Gosewisch, A., Melzer, H. I., Kaiser, L., Bartenstein, P., Böning, G., Rominger, A., & Cumming, P. (2021). Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: Application to mCRPC patients receiving Lu-177-PSMA-I&T. EJNMMI Physics, 8(1), Article 26. https://doi.org/10.1186/s40658-021-00369-4
  7. Gosewisch, A., Ilhan, H., Tattenberg, S., Mairani, A., Parodi, K., Brosch-Lenz, J., Kaiser, L., Zacherl, M. J., Bartenstein, P., Todd-Pokropek, A., & Böning, G. (2019). 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT. EJNMMI Research, 9(1), Article 76. https://doi.org/10.1186/s13550-019-0548-z
  8. Goetz, T. I., Lang, E. W., Prante, O., Maier, A., Schmidkonz, C., Kuwert, T., & Ritt, P. (2020). Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent $^{177}$Lu-DOTATOC therapy. Annals of Nuclear Medicine, 34(4), 244–253. https://doi.org/10.1007/s12149-020-01440-3
  9. Pacilio, M., Lanconelli, N., Lo Meo, S., Bellesi, L., Cattani, F., Chiaramida, P., Conte, L., Cremonesi, M., De Denaro, M., Ferrari, M. E., Pedroli, G., & Torres, L. (2009). Differences among Monte Carlo codes in the calculations of voxel S values for radionuclide targeted therapy and analysis of their impact on absorbed dose evaluations. Medical Physics, 36(5), 1543–1552. https://doi.org/10.1118/1.3103401
  10. Lee, M. S., Kim, J. H., Paeng, J. C., Kang, K. W., Lee, J. S., & Lee, D. S. (2018). Whole-body voxel-based personalized dosimetry: The multiple voxel S-value approach for heterogeneous media with nonuniform activity distributions. Journal of Nuclear Medicine, 59(7), 1133–1139. https://doi.org/10.2967/jnumed.117.201095
  11. Ljungberg, M., Celler, A., Konijnenberg, M. W., Eckerman, K. F., Dewaraja, Y. K., Sgouros, G., & SNMMI MIRD Committee. (2016). MIRD Pamphlet No. 26: Joint EANM/MIRD guidelines for quantitative $^{177}$Lu SPECT applied for dosimetry of radiopharmaceutical therapy. Journal of Nuclear Medicine, 57(1), 151–162. https://doi.org/10.2967/jnumed.115.159012
  12. Forrer, F., Krenning, E. P., Kooij, P. P., Bernard, B. F., Konijnenberg, M. W., Bakker, W. H., de Jong, M., & Kwekkeboom, D. J. (2009). Bone marrow dosimetry in peptide receptor radionuclide therapy with [$^{177}$Lu-DOTA$^0$,Tyr$^3$]octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 36(7), 1138–1146. https://doi.org/10.1007/s00259-009-1072-6
  13. Hagmarker, L., Svensson, J., Ryden, T., Van Essen, M., Sundlöv, A., Tennvall, J., & Sjögreen-Gleisner, K. (2019). Bone marrow absorbed doses and correlations with hematologic response during $^{177}$Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases. Journal of Nuclear Medicine, 60(10), 1406–1413. https://doi.org/10.2967/jnumed.118.225235
  14. Gupta, S. K., Singla, S., Thakral, P., & Bal, C. S. (2013). Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with $^{177}$Lu-DOTATATE. Clinical Nuclear Medicine, 38(3), 188–194. https://doi.org/10.1097/RLU.0b013e3182814ac1
  15. Sundlöv, A., Sjögreen-Gleisner, K., Svensson, J., Ljungberg, M., Olsson, T., Bernhardt, P., & Tennvall, J. (2017). Individualised $^{177}$Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 44(9), 1480–1489. https://doi.org/10.1007/s00259-017-3678-4
  16. Wehrmann, C., Senftleben, S., Zachert, C., Müller, D., & Baum, R. P. (2007). Results of individual patient dosimetry in peptide receptor radionuclide therapy with $^{177}$Lu DOTA-TATE and $^{177}$Lu DOTA-NOC. Cancer Biotherapy and Radiopharmaceuticals, 22(3), 406–416. https://doi.org/10.1089/cbr.2006.325
  17. Gosewisch, A., Delker, A., Tattenberg, S., Ilhan, H., Todica, A., Brosch-Lenz, J., Kaiser, L., Bartenstein, P., & Böning, G. (2018). Patient-specific image-based bone marrow dosimetry in $^{177}$Lu-[DOTA$^0$,Tyr$^3$]-Octreotate and $^{177}$Lu-DKFZ-PSMA-617 therapy: Investigation of a new hybrid image approach. EJNMMI Research, 8(1), Article 76. https://doi.org/10.1186/s13550-018-0427-z
  18. Thakral, P., Sen, I., Pant, V., Das, S. S., Malhotra, S., Gupta, S. K., & Bal, C. S. (2018). Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using $^{177}$Lu DOTATATE and capecitabine/temozolomide (CAP/TEM). The British Journal of Radiology, 91(1091), Article 20170172. https://doi.org/10.1259/bjr.20170172
  19. Seregni, E., Maccauro, M., Coliva, A., Chiesa, C., Botti, C., Aliberti, G., Martinetti, A., Lorenzoni, A., & Bombardieri, E. (2014). Treatment with tandem [$^{90}$Y]DOTA-TATE and [$^{177}$Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy. European Journal of Nuclear Medicine and Molecular Imaging, 41(2), 223–230. https://doi.org/10.1007/s00259-013-2578-5
  20. Sandström, M., Garske-Uromán, U., Granberg, D., Sundin, A., Lundqvist, H., Lubberink, M., & Eriksson, B. (2013). Individualized dosimetry of kidney and bone marrow in patients undergoing $^{177}$Lu-DOTA-octreotate treatment. Journal of Nuclear Medicine, 54(1), 33–41. https://doi.org/10.2967/jnumed.112.107524
  21. Hindorf, C., Glatting, G., Chiesa, C., Lindén, O., Flux, G., & EANM Dosimetry Committee. (2010). EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 37(6), 1238–1250. https://doi.org/10.1007/s00259-010-1422-4
  22. Fedorov, A., Beichel, R., Kalpathy-Cramer, J., Finet, J., Fillion-Robin, J. C., Pujol, S., Bauer, C., Jennings, D., Fennessy, F. M., Sonka, M., Buatti, J., Aylward, S. R., Miller, J. V., Pieper, S., & Kikinis, R. (2012). 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magnetic Resonance Imaging, 30(9), 1323–1341. https://doi.org/10.1016/j.mri.2012.05.001
  23. Jan, S., Santin, G., Strul, D., Staelens, S., Assié, K., Autret, D., Avner, S., Barbier, R., Bardiès, M., Bloomfield, P. M., Brasse, D., Breton, V., Bruyndonckx, P., Buvat, I., Chatziioannou, A. F., Choi, Y., Chung, Y. H., Comtat, C., Crispim, D., ... Morel, C. (2004). GATE: A simulation toolkit for PET and SPECT. Physics in Medicine & Biology, 49(19), 4543–4561. https://doi.org/10.1088/0031-9155/49/19/007
  24. Klein, S., Staring, M., Murphy, K., Viergever, M. A., & Pluim, J. P. W. (2010). elastix: A toolbox for intensity-based medical image registration. IEEE Transactions on Medical Imaging, 29(1), 196–205. https://doi.org/10.1109/TMI.2009.2035616
  25. Guerriero, F., Ferrari, M. E., Botta, F., Fioroni, F., Grassi, E., Versari, A., Sarnelli, A., Salvo, D., Cremonesi, M., & Pedroli, G. (2013). Kidney dosimetry in $^{177}$Lu and $^{90}$Y peptide receptor radionuclide therapy: Influence of image timing, time-activity integration method, and risk factors. BioMed Research International, 2013, Article 935351. https://doi.org/10.1155/2013/935351
  26. Schneider, W., Bortfeld, T., & Schlegel, W. (2000). Correlation between CT numbers and tissue parameters needed for Monte Carlo simulations of clinical dose distributions. Physics in Medicine & Biology, 45(2), 459–478. https://doi.org/10.1088/0031-9155/45/2/314
  27. Gupta, A., Lee, M. S., Kim, J. H., Shin, J. H., Pramanik, J., Lee, J. S., Kang, K. W., Paeng, J. C., & Lee, D. S. (2019). Preclinical voxel-based dosimetry through GATE Monte Carlo simulation using PET/CT imaging of mice. Physics in Medicine & Biology, 64(9), Article 095007. https://doi.org/10.1088/1361-6560/ab134b
  28. Gupta, A., Shin, J. H., Lee, M. S., Pramanik, J., Kang, K. W., Paeng, J. C., & Lee, D. S. (2019). Voxel-based dosimetry of iron oxide nanoparticle-conjugated Lu-177-labeled folic acid using SPECT/CT imaging of mice. Molecular Pharmaceutics, 16(4), 1498–1506. https://doi.org/10.1021/acs.molpharmaceut.8b01125
  29. Stabin, M. G., Sparks, R. B., & Crowe, E. (2005). OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. Journal of Nuclear Medicine, 46(6), 1023–1027.
  30. Kondev, F. G. (2019). Nuclear data sheets for A = 177. Nuclear Data Sheets, 159, 1–412. https://doi.org/10.1016/j.nds.2019.100514
  31. Stabin, M. G., & da Luz, L. C. (2002). Decay data for internal and external dose assessment. Health Physics, 83(4), 471–475. https://doi.org/10.1097/00004032-200210000-00004
  32. Stabin, M. G., Eckerman, K. F., Bolch, W. E., Bouchet, L. G., & Patton, P. W. (2002). Evolution and status of bone and marrow dose models. Cancer Biotherapy and Radiopharmaceuticals, 17(4), 427–433. https://doi.org/10.1089/108497802760363213
  33. Ilan, E., Sandström, M., Wassberg, C., Sundin, A., Garske-Román, U., Eriksson, B., & Lubberink, M. (2015). Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using $^{177}$Lu-DOTATATE. Journal of Nuclear Medicine, 56(2), 177–182. https://doi.org/10.2967/jnumed.114.148437
  34. Jahn, U., Ilan, E., Sandström, M., Garske-Román, U., Lubberink, M., & Sundin, A. (2020). $^{177}$Lu-DOTATATE peptide receptor radionuclide therapy: Dose response in small intestinal neuroendocrine tumors. Neuroendocrinology, 110(7-8), 662–670. https://doi.org/10.1159/000504001
  35. Jahn, U., Ilan, E., Sandström, M., Lubberink, M., Garske-Román, U., & Sundin, A. (2021). Peptide receptor radionuclide therapy (PRRT) with $^{177}$Lu-DOTATATE; differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms. Cancers, 13(5), Article 962. https://doi.org/10.3390/cancers13050962
  36. Garkavij, M., Nickel, M., Sjögreen-Gleisner, K., Ljungberg, M., Ohlsson, T., Wingårdh, K., & Tennvall, J. (2010). $^{177}$Lu-[DOTA$^0$,Tyr$^3$] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer, 116(4 Suppl), 1084–1092. https://doi.org/10.1002/cncr.24796
  37. Dewaraja, Y. K., Frey, E. C., Sgouros, G., Brill, A. B., Roberson, P., Zanzonico, P. B., Ljungberg, M., & SNMMI MIRD Committee. (2012). MIRD pamphlet No. 23: Quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. Journal of Nuclear Medicine, 53(8), 1310–1325. https://doi.org/10.2967/jnumed.111.100123
  38. Sgouros, G., Stabin, M., Erdi, Y., Akabani, G., Melhus, L., & Howell, R. W. (2000). Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Medical Physics, 27(9), 2150–2164. https://doi.org/10.1118/1.1288393
  39. Geyer, A. M., Schwarz, B. C., Hobbs, R. F., Sgouros, G., & Bolch, W. P. (2017). Quantitative impact of changes in marrow cellularity, skeletal size, and bone mineral density on active marrow dosimetry based upon a reference model. Medical Physics, 44(1), 272–283. https://doi.org/10.1002/mp.12002
  40. Hänscheid, H., Lapa, C., Buck, A. K., Lassmann, M., & Werner, R. A. (2018). Dose mapping after endoradiotherapy with $^{177}$Lu-DOTATATE/DOTATOC by a single measurement after 4 days. Journal of Nuclear Medicine, 59(1), 75–81. https://doi.org/10.2967/jnumed.117.193706
  41. Lee, M. S., Hwang, D., Kim, J. H., & Lee, J. S. (2019). Deep-dose: A voxel dose estimation method using deep convolutional neural network for personalized internal dosimetry. Scientific Reports, 9, Article 10308. https://doi.org/10.1038/s41598-019-46620-y
  42. Götz, T. I., Schmidkonz, C., Chen, S., Al-Baddai, S., Kuwert, T., & Lang, E. W. (2020). A deep learning approach to radiation dose estimation. Physics in Medicine & Biology, 65(3), Article 036007. https://doi.org/10.1088/1361-6560/ab65dc
  43. Akhavanallaf, A., Shiri, I., Arabi, H., & Zaidi, H. (2021). Whole-body voxel-based internal dosimetry using deep learning. European Journal of Nuclear Medicine and Molecular Imaging, 48(3), 670–682. https://doi.org/10.1007/s00259-020-05013-4

Cite

Kim KM, Lee MS, Suh MS, et al. Comparison of voxel S-value methods for personalized voxel-based dosimetry of 177Lu-DOTATATE. Med Phys.2022;49:1888–1901. https://doi.org/10.1002/mp.15444

COPY CITATION Copied!
VIEW RESEARCH HERE